Press Release

Histone Deacetylase Inhibitors Market Statistics, Size, Share, Key Companies, Growth, And Regional Forecast To 2026

Histone Deacetylase Inhibitors Market report covers top players as Vitamin D Testing Market report covers top players as F. Hoffmann-La Roche Ltd, DiaSorin S.p.A., Abbott, bioMérieux SA, Siemens Healthcare GmbH, Beckman Coulter, Inc., RECIPE Chemicals + Instruments GmbH, Quidel Corporation, Thermo Fisher Scientific, Immunodiagnostic Systems

The rising prevalence of cancer all around the globe is augmenting the global histone deacetylase inhibitors market, says Fortune Business Insights in their recent study. The study is titled, “Histone Deacetylase Inhibitors Market Size, Share and Global Trend by Class (Class I HDACs, Class II HDACS, Class III HDACs, Class IV HDACs), Application (Oncology, Neurology), End User (Hospitals, Academic & research institutes, Pharmaceutical companies) and Geography Forecast till 2026,”, and it states the rise in demand for treating cancer has brought lucrative growth opportunities for the market globally.

Browse Complete Report Details at

Some of the major companies that are present in the Global Histone Deacetylase Inhibitors Market are;

  • Merck KGaA
  • Medivir AB
  • Cetya Therapeutics
  • BioVision Inc.
  • R&D Systems, Inc.
  • Mirati Therapeutics
  • Abcam plc.
  • TCI Chemicals (India) Pvt. Ltd.
  • InvivoGen, and other players.

Fortune Business Insights foresees the cancer segment to account for the largest share in the market, due to its rising prevalence. Increasing expenditure on healthcare especially for treatment of cancer is helping the cancer segment lead the market.

Cancer Prevalence to Aid in Favor of Market

Various factors are responsible for the growth of the global histone deacetylase market including the increasing number of cancer cases as mentioned above. Other factors include the presence of skilled professionals in developed regions, increasing number of neurological disorders and tumor cases, and supportive reimbursement policies by governments. As per the World Health Organization, the second major cause of death in the world is cancer. In 2018, cancer was the cause of death in an estimated 9.6 million people around the world.

On the flipside, the market may face challenges in terms of inadequate reimbursement policies and uncertainty issues related to for histone deacetylase inhibitors. However, rise in awareness about various chronic diseases and the availability of diagnostics for treating such diseases will help the market gain momentum in the coming years.

Get Sample PDF Brochure at

Segmentation for Histone Deacetylase Inhibitors Market 

By Class 

  • Class I HDACs
  • Class II HDACS
  • Class III HDACs
  • Class IV HDACs.

By Application

  • Oncology
  • Neurology
  • Others

By End User

  • Hospitals,
  • Academic & research institutes
  • Pharmaceutical companies

By Geography 

Market to Gain Impetus from Government Reimbursement Policies

From a geographical standpoint, the global histone deacetylase inhibitors market is dominated by North America on account of rising prevalence of neurological disorders and cancer. The American Cancer Society states an estimated 12% of women in the U.S. develop breast cancer during their lifetime. The report also stated an estimate of 2300 men in the U.S. to be diagnosed with breast cancer. This, coupled with, the high acceptance of histone deacetylase inhibitors in developed nations of Canada and the U.S. is likely to help North America continue to dominate the market during the forecast period too.

On the other hand, Europe and Asia Pacific regions are anticipated to grow at faster rates owing to the increasing number of neurological disorder cases and the improving healthcare facilities in the respective regions. Besides this, the surge in demand for advanced treatment by a large number of patients is a major factor propelling growth in both regions.

Speak To Analyst at

Major vendors in the global histone deacetylase inhibitors market are focusing on strategies such as company collaborations, new product launches, mergers and acquisitions. They are also investing huge sums in research and development for creating innovative drugs. To site and instance, interim data of Phase 2 study evaluating pracinostat was announced in December 2018, by Helsinn Healthcare S.A.  Pracinostat is a histone deacetylase inhibitor that combines with azacitadine for treating patients suffering from higher stage of Myelodysplastic Syndrome (MDS) or IPSS-R high. Some of the players operating in the global histone deacetylase inhibitors market are Abcam plc., Cetya Therapeutics, R&D Systems, Inc., Mirati Therapeutics, TCI Chemicals (India) Pvt. Ltd., InvivoGen, BioVision Inc., Medivir AB, and Merck KGaA.


What is the market size and growth rate of the global and regional market by various segments?

What is the market size and growth rate of the market for selective countries?

Which region or sub-segment is expected to drive the market in the forecast period?

What Factors are estimated to drive and restrain the market growth?

What are the key technological and market trends shaping the market?

What are the key opportunities in the market?

What are the key companies operating in the market?

Which company accounted for the highest market share?

Why Choose Fortune Business Insights?

More Trending Topics from Fortune Business Insights:

Global Veterinary Clostridium Vaccine Market to Exhibit Growth Fueled by Rising Prevalence of Zoonotic Diseases


Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *